Dominique G. Larrey

Is it too early to dismiss corticosteroids in CDK4/6 inhibitor-induced liver injury?

Journal: JHEP reports : innovation in hepatology

Published: July 16, 2026

Long-term treatment of homozygous familial hypercholesterolemia with lomitapide: 11 years of safety and effectiveness findings from the Lomitapide Observational Worldwide Evaluation Registry.

Journal: Journal of clinical lipidology

Published: May 12, 2026

Correction: Liver Safety of the Dual Neurokinin‑1/‑3 Receptor Antagonist Elinzanetant.

Journal: Drug safety

Published: April 17, 2026

Liver biopsy findings and clinical correlates in immune-mediated liver injury from checkpoint inhibitors.

Journal: Hepatology communications

Published: March 11, 2026

HLA-B44 Alleles and HLA-DQA103:01 as Genetic Risk Factors for Drug-Induced Liver Injury due to Fluoroquinolones.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: February 19, 2026

Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant.

Journal: Drug safety

Published: September 16, 2025

Features and Outcomes of 280 Patients With Idiosyncratic Drug-Induced Liver Injury: The REFHEPS Prospective Study.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: June 04, 2025

Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert Consensus.

Journal: Drug safety

Published: May 27, 2025

Identification of risk profiles for liver injury in adults with multiple sclerosis using artificial intelligence method.

Journal: Multiple sclerosis and related disorders

Published: May 05, 2025

Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre Study.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: July 08, 2024

Time to use the right classification to predict the severity of checkpoint inhibitor-induced liver injury, as assessed for causality using the updated RUCAM.

Journal: Alimentary pharmacology & therapeutics

Published: June 18, 2024

Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis.

Journal: Advances in therapy

Published: May 21, 2024

Is it too early to dismiss corticosteroids in CDK4/6 inhibitor-induced liver injury?

Is it too early to dismiss corticosteroids in CDK4/6 inhibitor-induced liver injury?

Long-term treatment of homozygous familial hypercholesterolemia with lomitapide: 11 years of safety and effectiveness findings from the Lomitapide Observational Worldwide Evaluation Registry.

Long-term treatment of homozygous familial hypercholesterolemia with lomitapide: 11 years of safety and effectiveness findings from the Lomitapide Observational Worldwide Evaluation Registry.

Correction: Liver Safety of the Dual Neurokinin‑1/‑3 Receptor Antagonist Elinzanetant.

Correction: Liver Safety of the Dual Neurokinin‑1/‑3 Receptor Antagonist Elinzanetant.

Liver biopsy findings and clinical correlates in immune-mediated liver injury from checkpoint inhibitors.

Liver biopsy findings and clinical correlates in immune-mediated liver injury from checkpoint inhibitors.

HLA-B*44 Alleles and HLA-DQA1*03:01 as Genetic Risk Factors for Drug-Induced Liver Injury due to Fluoroquinolones.

HLA-B*44 Alleles and HLA-DQA1*03:01 as Genetic Risk Factors for Drug-Induced Liver Injury due to Fluoroquinolones.

Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant.

Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant.

Features and Outcomes of 280 Patients With Idiosyncratic Drug-Induced Liver Injury: The REFHEPS Prospective Study.

Features and Outcomes of 280 Patients With Idiosyncratic Drug-Induced Liver Injury: The REFHEPS Prospective Study.

Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert Consensus.

Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert Consensus.

Identification of risk profiles for liver injury in adults with multiple sclerosis using artificial intelligence method.

Identification of risk profiles for liver injury in adults with multiple sclerosis using artificial intelligence method.

Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre Study.

Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre Study.

Time to use the right classification to predict the severity of checkpoint inhibitor-induced liver injury, as assessed for causality using the updated RUCAM.

Time to use the right classification to predict the severity of checkpoint inhibitor-induced liver injury, as assessed for causality using the updated RUCAM.

Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis.

Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis.

HLA-B44 Alleles and HLA-DQA103:01 as Genetic Risk Factors for Drug-Induced Liver Injury due to Fluoroquinolones.

HLA-B44 Alleles and HLA-DQA103:01 as Genetic Risk Factors for Drug-Induced Liver Injury due to Fluoroquinolones.